Condition: Hidradenitis Suppurativa (HS) · Sponsor: Incyte Corporation
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
This description comes directly from the study's public registry record.
Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com
Incyte Corporation Call Center (ex-US) · +800 00027423 · eumedinfo@incyte.com
Always discuss trial participation with your own doctor first.
| University of Alabama At Birmingham | Birmingham, Alabama, United States | Recruiting |
| Medical Dermatology Specialists Phoenix | Phoenix, Arizona, United States | Recruiting |
| Saguaro Dermatology | Phoenix, Arizona, United States | Recruiting |
| Uconn Health | Farmington, Connecticut, United States | Recruiting |
| University of Miami Miller School of Medicine | Miami, Florida, United States | Recruiting |
| Skin Research of South Florida, Llc | Miami, Florida, United States | Recruiting |
| Trueblue Clinical Research | Tampa, Florida, United States | Recruiting |
| Advanced Medical Research Pc | Sandy Springs, Georgia, United States | Recruiting |
| Endeavor Health Medical Group | Skokie, Illinois, United States | Recruiting |
| Dermatology Skin Cancer Center Leawood | Leawood, Kansas, United States | Recruiting |
| Equity Medical | Bowling Green, Kentucky, United States | Recruiting |
| Johns Hopkins Univ Schl of Medicine | Baltimore, Maryland, United States | Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07213973